Quick Facts
| Property | Value |
|---|---|
| Category | Dual GLP-1 / GIP Receptor Agonist |
| Risk Level | Moderate |
| Administration | Subcutaneous Injection |
| Typical Frequency | Once Weekly |
| Estimated Half-Life | Approximately 5 Days |
| Primary Research Interest | Fat Loss / Appetite Regulation / Glucose Control |
This material is provided strictly for educational and informational purposes related to peptide research and metabolic compounds. Tirzepatide is a potent biologically active medication with potentially significant physiological effects and side effects. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 60 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 3 mL
- Final Concentration: 20.0 mg/mL
At this concentration:
• 2.5 mg = 0.125 mL (12.5 units)
2. Route of Administration
Tirzepatide is most commonly administered as a subcutaneous injectable compound.
- Primary Route: SubQ Injection
- Preferred Timing: Morning administration
- Administration Notes: Commonly discussed in fasted-state protocols
3. Typical Research Protocols
- Product Strength: 20.0 mg/mL
- Typical Delivered Amount: 2.5 mg (12.5 units) once weekly, increasing by 2.5 mg every 4 weeks as needed
- Frequency: Once weekly, preferably in the morning while fasted
- Cycle Length: Indefinite
- Special Notes: Doses above 15 mg weekly are generally not discussed in clinical use contexts
4. Summary
Tirzepatide is a dual incretin receptor agonist that activates both GLP-1 and GIP signaling pathways.
Research and clinical interest in the compound primarily centers around weight reduction, appetite suppression, glycemic control, and metabolic regulation.
5. Mechanism of Action
Tirzepatide functions by activating both glucagon-like peptide-1 (GLP-1) receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors.
These pathways influence:
- Insulin secretion
- Appetite signaling
- Gastric emptying
- Blood glucose regulation
- Satiety mechanisms
Dual agonism is believed to contribute to enhanced metabolic effects compared to single-pathway GLP-1 agonists alone.
6. Potential Benefits
- Significant appetite suppression
- Reduced caloric intake
- Substantial body weight reduction
- Improved glycemic control
- Potential improvements in insulin sensitivity
- Reduced food preoccupation in some anecdotal reports
7. Potential Risks / Side Effects
Moderate
- Nausea
- Vomiting
- Constipation
- Diarrhea
- Fatigue
- Reduced appetite to problematic levels
- Potential gallbladder complications
- Risk of hypoglycemia when combined with other glucose-lowering medications
8. Half-Life
Tirzepatide has an estimated half-life of approximately 5 days, supporting once-weekly administration discussions.
Steady-state concentrations generally require multiple weeks of consistent administration.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- History of pancreatitis
- Severe gastrointestinal disease
- Pregnancy or breastfeeding
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
11. Research References
- PubMed
- NIH Publications
- SURPASS clinical trial program
- Peer-reviewed metabolic disease journals
CKF Tide Tables 